

Scientific program – 18th Central European Lung Cancer Conference and Best of WCLC 2019

21 November 2019 Thursday	
12:00-12:30	Registration
12:30-13:00	Opening remarks
13:00-14:30	<p>Session 1. Prevention, Screening, Early diagnosis <i>Chairs: Anna Kerpel-Fronius, Gábor Kovács</i></p> <p>Revising incidence and mortality of lung cancer in Central Europe: Epidemiology overview from Hungary based on National Health Insurance Fund Database <u>Zoltán Kiss</u> <i>MSD Pharma Ltd., Budapest, Hungary</i></p> <p>Results of the Nelson study and what would I do differently - knowing what I know today <u>Carlijn M. van der Aalst</u> <i>Nelson and Robinsca trial, The Netherlands</i></p> <p>First experiences with a national lung cancer screening program <u>Ante Marusic</u> <i>University Medical Centre Zagreb, Radiology, Croatia</i></p> <p>Fact, fiction, fantasy - the role of artificial intelligence in respiratory medicine <u>Joris Wakkie</u> <i>Aidence B.V., Amsterdam, the Netherlands.</i></p> <p>Discussion</p>
14:30-15:30	<p>Boehringer Ingelheim Symposium - Making 1st and 2nd line treatment decisions for advanced NSCLC <i>Chair: Gyula Ostoros</i></p> <p>Welcome and introductions <u>Gyula Ostoros</u> <i>National Korányi Institute of Pulmonology, Budapest, Hungary</i></p> <p>Maximizing Time on EGFR TKI Therapy <u>Tanja Cufer</u> <i>University Clinic Golnik, Golnik, Slovenia</i></p> <p>Panel Discussion <u>Pavel Badurak</u> <i>Oncology Center Marii Skłodowskiej-Curie, Nowotworów Płuca i Klatki Piersiowej Clinic, Warsaw, Poland</i></p> <p><u>Robert Pirker</u> <i>Department of Medicine I, Medical University of Vienna, Austria</i></p> <p>New learnings on nintedanib in adenocarcinoma treatment <u>Lilla Tamasi</u> <i>Semmelweis University, Budapest, Hungary</i></p> <p>Panel Discussion <u>Pavel Badurak</u> <i>Oncology Center Marii Skłodowskiej-Curie, Nowotworów Płuca i Klatki Piersiowej Clinic, Warsaw, Poland</i></p> <p><u>Robert Pirker</u> <i>Department of Medicine I, Medical University of Vienna, Austria</i></p> <p>Closing word</p>

	<p><u>Gyula Ostoros</u> National Korányi Institute of Pulmonology, Budapest, Hungary</p>
15:30-16:00	Coffee break
16:00-17:00	<p>Session 2. New waves in lung cancer management Chairs: Judit Moldvay, József Tímár</p> <p>Improved Survival Prognostication of Cancer Patients combining Proteomics - Histopathological Characterization and Clinical Data Studies within the European Cancer Moonshot Center <u>György Marko-Varga</u> Lund University, Lund, Sweden</p> <p>Diagnostic quantification of DNA repair pathway aberrations in lung cancer is an important step towards personalized therapy <u>Zoltán Szállási</u> Harvard Medical School, Boston, USA</p> <p>New targets in small cell lung cancer <u>Balázs Döme</u> Medical University of Vienna, Austria; National Korányi Institute of Pulmonology-Semmelweis University, Budapest, Hungary</p> <p>Discussion</p>
17:00-18:00	<p>AstraZeneca Symposium - Transforming landscape of non small cell lung cancer Chair: Zsolt Pápai Székely</p> <p>Treatment with curative intent in stage III NSCLC – synergies between immunoncology and chemoradiation <u>Karmen Stanic</u> Institute of Oncology Ljubljana, Department of Radiotherapy, Slovenia</p> <p>Optimizing treatment of EGFR mutated IV. st. NSCLC with brain metastasis <u>Krisztina Bogos</u> National Korányi Institute of Pulmonology, Budapest, Hungary</p>
18:00	Greetings, Welcome reception

	<p>22 November 2019 Friday</p>
<p>09:00-10:00</p>	<p>Session 3. Proffered papers Chairs: Veronika Sárosi, Lubos Petruzelka</p> <p>PP01 Lung Cancer in CE: identifying policy options to address the burden <u>Mary Bussell</u> <i>Economist Intelligence Unit, London, United Kingdom</i></p> <p>PP02 Lung Cancer Epidemiology of Hungarian Regions between 2011 and 2016 <u>Gabriella Gálffy</u>¹, Aladár Vastag², Krisztina Bogos³, Zoltán Kiss², Gyula Ostoros¹, Veronika Müller⁴, László Urbán⁵, Nóra Bittner⁶, Veronika Sárosi⁷, Zoltán Polányi², Zsófia Nagy-Erdei², Zoltán Vokó⁸, Balázs Nagy⁸, Krisztián Horváth⁸, György Rokszin⁹, Zsolt Abonyi-Tóth^{9,10}, Judit Moldvay^{11,12}, Lilla Tamási⁴ <i>¹Pulmonology Hospital Törökbálint, Hungary; ²MSD Pharma Hungary Ltd, Budapest, Hungary; ³Department of Pulmonology, National Korányi Institute of Pulmonology, Budapest, Hungary; ⁴Department of Pulmonology, Semmelweis University, Budapest, Hungary; ⁵Mátraháza Healthcare Center and University Teaching Hospital, Mátraháza, Hungary; ⁶University of Debrecen, Pulmonology Clinic, Debrecen, Hungary; ⁷Faculty of Medicine, University of Pécs, Pécs, Hungary; ⁸Eötvös Loránd University, Budapest, Hungary; ⁹RxTarget Ltd. Szolnok, Hungary; ¹⁰University of Veterinary Medicine Budapest, Hungary; ¹¹Department of Tumor Biology, National Korányi Institute of Pulmonology – Semmelweis University, Budapest, Hungary; ¹²MTA-SE NAP, Brain Metastasis Research Group, Hungarian Academy of Sciences, 2nd Department of Pathology, Semmelweis University, Budapest, Hungary</i></p> <p>PP03 Choosing the right path to personalised medicine in lung cancer: a single institution experience <u>Maximilian Hochmair</u> <i>Respiratory Oncology Unit, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Department of Respiratory and Critical Care Medicine, Vienna North Hospital – Klinik Floridsdorf, Vienna, Austria</i></p> <p>PP04 Clinical and Treatment Characteristics of Malignant Pleural Mesothelioma in Vojvodina and Survival Outcomes <u>Nensi Lalic</u>^{1,2}, Danica Sazdanic Velikic^{2,3}, Aleksandar Tepavac², Ivan Ergelasev^{4,5}, Marko Bojovic², Nevena Secen^{6,2} <i>¹University of Novi Sad, Faculty of Medicine, Department of Nursing, Novi Sad, Serbia; ²Institute for Pulmonary Diseases of Vojvodina, Clinic for Thoracic Oncology, Serbia; ³University of Novi Sad, Faculty of Medicine, Department of Geriatrics, Novi Sad, Serbia; ⁴Institute for Pulmonary Diseases of Vojvodina, Thoracic Surgery Clinic, Sremska Kamenica, Serbia; ⁵University of Novi Sad, Faculty of Medicine, Department of Surgery, Novi Sad, Serbia; ⁶University of Novi Sad, Faculty of Medicine, Department of Internal Medicine, Novi Sad, Serbia</i></p>
<p>10:00-11:00</p>	<p>Session 4. Translational research directions in lung cancer Chairs: Erika Tóth, Maximilian Hochmair</p> <p>Uncovering the immunostimulatory potential of PARP inhibitors in NSCLC <u>Roman Chabanon</u> <i>Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom</i></p> <p>Refining biomarker design in the light of lung cancer evolution <u>Dhruva Biswas</u> <i>University College London, London, United Kingdom</i></p> <p>Genomic evidence for metastasis formation and EGFR inhibitor resistance <u>Dávid Szüts</u> <i>Hungarian Academy of Sciences, Budapest, Hungary</i></p> <p>Discussion</p>

11:00-11:15	Coffee break
11:15-11:30	<p>Special welcome <u>Prof. Dr. Ildikó Horváth</u> <i>Minister of State for Health Care, Ministry of Human Capacities, Budapest, Hungary</i></p>
11:30-12:30	<p>BMS Symposium - ImmunOncology in NSCLC - The real breakthrough (Long term survival and real world evidences) Chair: Mirjana Rajer, Zoltán Balikó</p> <p>Navigating the 1L NSCLC Landscape <u>Gabriella Gálffy</u> <i>Onco-Pulmonology Department and Research and Education, Pest County Pulmonology Hospital, Törökbálint, Hungary</i></p> <p>How IO has changed our clinical practice in Hungary <u>Veronika Müller</u> <i>Department of Pulmonology, Semmelweis University Faculty of Medicine, Hungary</i></p> <p>Real world data with nivolumab across different countries <u>Marko Jakopović</u> <i>University Hospital Centre Zagreb, Head of Department Clinic of Pulmonary Diseases Jordanovac, Croatia</i></p>
12:30-13:30	Lunch
13:30-14:00	<p>6th Petr Zatloukal Memorial Lecture Chairs: Robert Pirker, Gyula Ostoros</p> <p>Lung Cancer: Augmenting the Efficacy of Cancer Immunotherapy Through Interventions in the Gut Microbiome <u>Lubos Petruzelka</u> <i>Charles University in Prague, Czech Republic</i></p>
14:00-15:00	<p>Session 5. Proffered papers Chairs: Edit Csada, Wlodzimierz Olszewski</p> <p>PP05 The effect of EGFR polymorphism rs2293347 on the clinical outcome of advanced lung adenocarcinoma patients treated with EGFR TKIs <u>Jelena Spasic¹</u>, <u>Vera Jokic¹</u>, <u>Neda Nikolic¹</u>, <u>Vladimir Nikolic¹</u>, <u>Marija Ristic¹</u>, <u>Davorin Radosavljevic¹</u>, <u>Milena Cavic²</u> ¹<i>Clinic for Medical Oncology</i>, ²<i>Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia</i></p> <p>PP06 Differential diagnosis and management of pulmonary ground-glass nodules <u>Zoltán Szász¹</u>, <u>Ágnes Takler²</u>, <u>Zsuzsanna Szalai¹</u> ¹<i>Petz Aladár Teaching County Hospital, Pulmonology Department, Győr, Hungary</i>; ²<i>Petz Aladár Teaching County Hospital, Karolina Hospital, Radiology Department, Mosonmagyaróvár, Hungary</i></p> <p>PP07 Importance of early integration of palliative care into lung cancer management: total pain concept <u>Tomi Kovacevic^{1,2}</u> ¹<i>Faculty of Medicine, University of Novi Sad, Serbia</i>; ²<i>Institute of pulmonary diseases of Vojvodina, Sremska Kamenica, Serbia</i></p> <p>PP08 KRAS mutations predict response and outcome in advanced lung adenocarcinoma patients receiving first-line bevacizumab and platinum-based chemotherapy <u>Áron K Ghimessy^{1,2}</u>, <u>Áron Gellért¹</u>, <u>Erzsebet Schlegl³</u>, <u>Balazs Hegedus⁴</u>, <u>Erzsebet Raso⁵</u>, <u>Tamas Barbai⁵</u>, <u>Jozsef Timar⁵</u>, <u>Gyula Ostoros⁶</u>, <u>Zsolt Megyesfalvi¹</u>, <u>Balazs Gieszer¹</u>, <u>Judit Moldvay³</u>, <u>Ferenc</u></p>

	<p>Renyi-Vamos¹, Zoltan Lohinai³, Mir Alizera Hoda⁷, Thomas Klikovits⁷, Walter Klepetko⁷, Viktoria Laszlo⁷, Balázs Döme⁷</p> <p>¹National Institute of Oncology, Thoracic Surgery, Hungary; ²Semmelweis University, Department of Thoracic Surgery, Budapest, Hungary; ³National Koranyi Institute of Pulmonology, Department of Tumor Biology, Budapest, Hungary; ⁴Ruhrlandklinik, University Duisburg-Essen, Department of Thoracic Surgery, Essen, Germany; ⁵Semmelweis University, 2nd Department of Pathology, Budapest, Hungary; ⁶National Korányi Institute of Pulmonology, 8th Department of Pulmonology, Budapest, Hungary; ⁷Comprehensive Cancer Centre Vienna, Medical University Vienna, Division of Thoracic Surgery, Department of Surgery, Vienna, Austria</p>
15:00-16:00	<p>MSD Symposium - Trusting the evidences - NSCLC treatment options in the frontline Chair: Maximilian Hochmair</p> <p>Welcome and Introduction <u>Maximilian Hochmair</u> <i>Respiratory Oncology Unit, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Department of Respiratory and Critical Care Medicine, Vienna North Hospital – Klinik Floridsdorf, Vienna, Austria</i></p> <p>Scientific Rationale of Use of ICPIs in 1L mNSCLC setting <u>Johan Vansteenkiste</u> <i>Respiratory Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium</i></p> <p>Two cases, multiple questions Reevaluating treatment choices in 1L mNSCLC: IO/chemotherapy combination or IO monotherapy? <u>Gyula Ostoros</u> <i>National Korányi Institute of Pulmonology, Budapest, Hungary</i></p>
16:00-16:30	<i>Coffee break</i>
16:30-18:00	<p>Session 6. Multidisciplinary tumor board Moderator: Gabriella Gálffy, Robert Pirker</p> <p>Board: Ales Ryska - Pathology László Agócs - Thoracic surgery Jana Skrickova - Oncology András Bajcsay - Radiotherapy Helmut Prosch - Radiology Zsolt Pápai-Székely - Oncology</p> <p>Chemoradiotherapy of locally advanced lung cancer prior to implementation of immunotherapy <u>Milada Zemanova</u> <i>Charles University, Prague, Czech Republic</i></p> <p>Combinations in immunotherapy of lung cancer <u>Bojan Zaric</u> <i>Institute for Pulmonary Diseases of Vojvodina, Clinic for Pulmonary Oncology, Faculty of Medicine, University of Novi Sad, Serbia</i></p> <p>Long-term survival in stage IV lung adenocarcinoma – A case report <u>Lilla Tamási</u> <i>Department of Pulmonology, Semmelweis University, Budapest, Hungary</i></p> <p>Operable disease followed by systemic relapse including brain metastases <u>Robert Pirker, Helmut Prosch</u> <i>Department of Medicine I, Medical University of Vienna, Austria</i></p>
18:00-18:15	<p>Poster award Chair: Klára Szondy, Jelena Spasic, Jana Skrickova</p> <p style="text-align: center;">Electronic Poster Board I.</p>

EP01**Five-year progression free survival in patients with advanced NSCLC treated with EGFR-TKIs**

Peter Berzinec¹, P Kasan², J. Mazal³, I, Andrassina⁴, A. Cipkova⁵, M. Bodorova⁶, P. Demo⁷, G. Chowaniecova¹, I. Jancokova⁸, I. Kuliskova⁹, M. Martak², I. Palkovacsova¹⁰, M. Urda³, M. Vesela², L. Plank¹¹

¹Specialised Hospital of St. Zoerardus Zobor, Nitra, Slovak Republic; ²Comenius University Hospital, Bratislava, Slovak Republic; ³F. D. Roosevelt University Hospital, Banska Bystrica, Slovak Republic; ⁴P.J. Safarik University, Kosice, Slovak Republic; ⁵East Slovak Republic Oncology Institute, Kosice, Slovak Republic; ⁶Central Military Hospital, Ruzomberok, Slovak Republic; ⁷Faculty Hospital, Nove Zamky, Slovak Republic; ⁸Outpatient Oncology Department, Prievidza, Slovak Republic; ⁹University Hospital, Martin, Slovak Republic; ¹⁰Hospital Rimavska Sobota, Rimavska Sobota, Slovak Republic; ¹¹Martin's Biopsy Center, Martin, Slovak Republic

EP02**A case of a lung cancer patient successfully treated with alectinib**

Tünde Nagy¹

¹National Institute of Oncology, Budapest, Hungary

EP03**Targeted therapy instead of surgery. Case reopr.**

Attila Lieber¹, Nóra Bittner¹

¹Pulmonology Department, University of Debrecen Faculty of Medicine, Debrecen, Hungary

EP04**First line treatment with mono pembrolizumab in high PD-L1 positivite NSCLC patient**

Krisztina Bábel¹, Krisztina Csiszár¹, Judit Pápay², Ilona Kovalszky², Csaba Bödör², Gergő Papp², Gabriella Gálffy¹

¹Tüdőgyógyintézet Törökbálint - II. Osztály, Törökbálint, Hungary; ²1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

EP05**First-line treatment of a patient with stage IVB pulmonary adenocarcinoma with combined platinum-based chemotherapy and immunotherapy**

Eszter Gáspár¹, Judit Pápay², Csaba Bödör², Gergő Papp², Gabriella Gálffy¹

¹Pulmonology Hospital Törökbálint, Törökbálint, Hungary; ²1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

Electronic Poster Board II.**EP06****The success story of professionalism, the luck and will to live**

Tímea Lovas¹, Erzsébet Gergely-Farnos¹, Attila Bagó², Gergő Dávid Nagy², András Matolcsy³, Lilla Reiningner³, Csaba Bödör³, Gergő Papp³, Gabriella Gálffy¹

¹Pulmonology Hospital Törökbálint, Törökbálint, Hungary; ²National Institute of Clinical Neuroscience, Budapest, Hungary; ³1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary

EP07**Successful treatment of NSCLC exon 19 mutant patient with second generation EGFR-TKI inhibitor**

Réka Hécz¹, Rita Puskas¹, Judit Pápay², Ilona Kovalski², Attila Bagó³, Gabriella Gálffy¹

¹Tüdőgyógyintézet Törökbálint, Törökbálint, Hungary; ²1st Department of Pathology, Semmelweis University, Budapest, Hungary; ³Department of Neuro-Oncology, National Institute of Clinical Neurosciences, Budapest, Hungary

EP08**Pushing the boundaries: a convincing case in treating CNS metastasis with alectinib**

Dóra Paróczai¹, Edit Csada¹

¹Department of Pulmonology, University of Szeged, Szeged, Hungary

EP09**Effective IOcombination therapy in a patient with EGFR-mutation after progression**

Eszter Czibula¹, Krisztina Bogos¹

¹National Korányi Institute of Pulmonology, Budapest, Hungary

EP10**6 years long survival analysis of lung cancer patients in Hungary diagnosed between 2011 and 2016**

Krisztina Bogos¹, Zoltan Kiss², Gabriella Gálffy³, Lilla Tamási⁴, Gyula Ostoros¹, Veronika Müller⁴, László Urbán⁵, Nóra Bittner⁶, Veronika Sárosi⁷, Aladár Vastag², Zoltán Polányi², Zsófia Nagy-Erdei², Zoltán Vokó⁸, Balázs Nagy⁸, Krisztián Horváth⁸, György Rokzin⁹, Zsolt Abonyi-Tóth^{9,10}, Judit Moldvay^{11,12}

¹National Korányi Institute of Pulmonology, Budapest, Hungary; ²MSD Pharma Hungary Ltd, Budapest, Hungary; ³Pulmonology Hospital Törökbálint, Hungary; ⁴Department of Pulmonology, Semmelweis University, Budapest, Hungary; ⁵Mátrahaza Healthcare Center and University Teaching Hospital, Mátrahaza, Hungary; ⁶University of Debrecen, Debrecen, Hungary; ⁷Faculty of Medicine, University of Pécs, Pécs, Hungary; ⁸Eötvös Loránd University, Budapest, Hungary; ⁹RxTarget Ltd, Szolnok, Hungary; ¹⁰University of Veterinary Medicine Budapest, Hungary; ¹¹Department of Tumor Biology, National Korányi Institute of Pulmonology, Semmelweis University, Budapest, Hungary; ¹²2nd Department of Pathology, MTA-SE NAP, Brain Metastasis Research Group, Hungary

Electronic Poster Board III.**EP11****High Dose Rate Endobronchial Brachytherapy (HDR-EBBT) in the Management of the Presence of Lung Atelectasis**

Nensi Lalic^{1,2}, Evica Budisin², Aleksandar Tepavac², Ivan Ergelasev^{3,4}, Marko Bojovic²

¹University of Novi Sad, Faculty of Medicine, Department of Nursing, Novi Sad, Serbia; ²Institute for Pulmonary Diseases of Vojvodina, Clinic for Thoracic Oncology, Sremska Kamenica, Serbia; ³University of Novi Sad, Faculty of Medicine, Department of Surgery, Novi Sad, Serbia; ⁴Institute for Pulmonary Diseases of Vojvodina, Thoracic Surgery Clinic, Sremska Kamenica, Serbia

EP12**Real-world data on immune checkpoint inhibitors efficacy in non-small cell lung cancer: a single centre experience**

Marija Ivanovic¹, Ana Herzog², Izidor Kern³, Mile Kovacevic³, Tanja Cufer^{3,4}

¹University Medical Centre Maribor, Department of Oncology, Maribor, Slovenia; ²University of Ljubljana, Faculty of Computer and Information Science, Ljubljana, Slovenia; ³University Clinic Golnik, Golnik, Slovenia; ⁴University of Ljubljana, Medical Faculty Ljubljana, Ljubljana, Slovenia

EP13**Review of the LDCT screening paradigm of lung cancer, proposal for combined use of blood testing and LDCT**

Laszlo Takacs¹, Jozsef Lazar²

¹Biosystems International Kft / University of Debrecen, Faculty of Medicine, Department of Genetics, Debrecen, Hungary; ²Biosystems International Kft, Debrecen, Hungary

EP14**Molecular Analysis of the Biomarker Value of C9 Epitopes in Lung Cancer**

Ilona Tornyi¹, József Lázár², Aladár Pettkó-Szandtner³, Lora Szilágyi², Éva Hunyadi-Gulyás³, Katalin Medzihradzsky³, László Takács^{1,2}

¹University of Debrecen, Department of Human Genetics, Debrecen, Hungary; ²Biosystems International Kft, Debrecen, Hungary; ³Biological Research Center, Proteomics Laboratory, Szeged, Hungary

EP15**Plasma protein epitomics profiling detects lung cancer association of various clinical parameters (gender, BMI, copd, staging)**

Jozsef Lazar¹, Saima Nur², Peter Antal-Szalmas³, Gyorgy Losonczy⁴, Maria Szilasi⁵, Tamas Kardos⁵, Klara Szondy⁴, Gabriella Galffy^{4,6}, Eszter Csanky⁷, Attila Somfay⁸ and Laszlo Takacs¹

¹Biosystems International Kft, Debrecen, Hungary; ²University of Debrecen, Faculty of Medicine, Department of Human Genetics, Debrecen, Hungary; ³University of Debrecen, Faculty of Medicine, Department of Laboratory Medicine, Debrecen, Hungary; ⁴Semmelweis University, Faculty of Medicine, Department of Pulmonology, Budapest, Hungary; ⁵University of Debrecen, Faculty of Medicine, Department of Pulmonology, Debrecen, Hungary; ⁶Tüdőgyógyintézet Törökbálint, Törökbálint, Hungary; ⁷Miskolci Semmelweis Ignác Egészségügyi Központ és Egyetemi Oktató Kórház, Department of Pulmonology, Miskolc, Hungary; ⁸University of Szeged, Faculty of Medicine, Department of Pulmonology, Deszk, Hungary

Electronic Poster Board IV.

EP16

The high correlation of the proportion of PD-L1 positive tumor cells in primary lung cancer and their corresponding brain metastases is not affected by oncotherapy

Judit Moldvay^{1,2}, Vanda Téglási³, Orsolya Pipek⁴, Rita Lózsa⁵, Kinga Berta⁵, Dávid Szüts⁵, Tünde Harkó⁶, Pál Vadász⁷, Lívia Rojkó⁸, Balázs Döme^{2,9}, Attila G. Bagó¹⁰, József Tímár^{2,11}, Zoltán Szállási^{2,12,13}, Lilla Reiniger^{2,3}

¹Department of Tumor Biology, National Korányi Institute of Pulmonology–Semmelweis University, Budapest, Hungary; ²MTA-SE NAP, Brain Metastasis Research Group, Hungarian Academy of Sciences, ^{2nd} Department of Pathology, Semmelweis University, Budapest, Hungary; ³1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; ⁴Department of Physics of Complex Systems, Eötvös Loránd University, Budapest, Hungary; ⁵Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary; ⁶Department of Pathology, National Korányi Institute of Pulmonology, Budapest, Hungary; ⁷Department of Thoracic Surgery, National Korányi Institute of Pulmonology, Budapest, Hungary; ⁸VI. Department of Pulmonology, National Korányi Institute of Pulmonology, Budapest, Hungary; ⁹Division of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; ¹⁰Department of Neurooncology, National Institute of Clinical Neurosciences, Budapest, Hungary; ¹¹Hungarian Academy of Sciences–Semmelweis University, Molecular Oncology Research Unit, Budapest, Hungary; ¹²Computational Health Informatics Program, Boston Children's Hospital, USA, Harvard Medical School, Boston, MA, United States; ¹³Danish Cancer Society Research Center, Copenhagen, Denmark

EP17

Correlation between tumor necrosis and PD-L1/PD-1 expression in lung adenocarcinoma

Judit Moldvay^{1,2}, Vanda Téglási³, Orsolya Pipek⁴, Lívia Rojkó⁵, Tibor Glasz⁶, Attila Vágvölgyi⁷, Ilona Kovalszky³, Márton Gyulai⁸, Zoltán Lohinai¹, Erzsébet Rásó⁹, József Tímár⁹, Balázs Döme^{1,10}, Zoltán Szállási^{2,11,12}, Lilla Reiniger^{2,3}

¹Department of Tumor Biology, National Korányi Institute of Pulmonology – Semmelweis University, Budapest, Hungary; ²MTA-SE NAP, Brain Metastasis Research Group, Hungarian Academy of Sciences, ^{2nd} Department of Pathology, Semmelweis University, Budapest, Hungary; ³1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; ⁴Department of Physics of Complex Systems, Eötvös Loránd University, Budapest, Hungary; ⁵VI. Department of Pulmonology, National Korányi Institute of Pulmonology, Budapest, Hungary; ⁶Department of Pathology, National Korányi Institute of Pulmonology, Budapest, Hungary; ⁷Department of Thoracic Surgery, National Korányi Institute of Pulmonology, Budapest, Hungary; ⁸2nd Department of Pulmonology, County Hospital of Pulmonology, Törökbálint, Hungary; ⁹2nd Department of Pathology, Semmelweis University, Budapest, Hungary; ¹⁰Division of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; ¹¹Children's Hospital Informatics Program at the Harvard–Massachusetts Institute of Technology Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, United States; ¹²Danish Cancer Society Research Center, Copenhagen, Denmark

EP18

Surgical experience in SCLC – a retrospective two –center study

Christian Lang¹, Thomas Klikovits¹, Mir Alireza Hoda¹, Walter Klepetko¹, Zsolt Megyesfalvi², Judit Moldvay², Balázs Döme^{1,2}

¹Medical University of Vienna, Austria; ²National Korányi Institute of Pulmonology, Budapest, Hungary

EP19

Early outcome, mortality and major morbidity after lung cancer surgery for primary carcinoma

Fadil Gradica¹, Lutfi Lisha¹, Dhimitraq Argjiri², Alma Cani³, Fahri Kokici³, Daniela Xhemalaj⁴, Ibrahim Avdiu⁵, Helidon Nina⁵, Alketa(Y) Pere⁵, Sali(M) Gradica⁶

¹University Hospital "Shefqet Ndroqi" Tirana Albania, Thoracic Surgery, Tirane, Albania; ²University Hospital "Shefqet Ndroqi" Tirana Albania, Pneumology, Tirane, Albania; ³University Hospital, Anestesia reanimation, Tirane, Albania; ⁴University Hospital "Shefqet Ndroqi" Tirana Albania, Pathology, Tirane, Albania; ⁵University Hospital Center "Mother Theresa", Oncology, Tirane, Albania; ⁶Public Pharmacy Service, Public Pharmacy service Kamez, Tirane, Albania

EP20

Spontaneous rib fractures: analyses our cases

Fadil Gradica¹, Lutfi Lisha¹, Dhimitraq Argjiri², Alma Cani³, Fahri Kokici³, Zef Perduka⁴, Klodian Gradica⁵, Aishe (R) Lala⁶

¹University Hospital "Shefqet Ndroqi" Tirana Albania, Thoracic Surgery, Tirane, Albania; ²University Hospital "Shefqet Ndroqi" Tirana Albania, Pneumology, Tirane, Albania; ³University Hospital "Shefqet Ndroqi" Tirana Albania, Anestesia reanimation, Tirane, Albania; ⁴Regional Public Hospital Rreshen, Internist, Rreshen, Albania; ⁵Public Pharmacy University, Student ,Pharmacy, Tirane, Albania; ⁶Public Pharmacy Service, Pharmacy Service, Tirane, Albania

Electronic Poster Board V.

EP21

Lung leiomyosarcoma

Morana Kosanovic Bajic¹, Kukulj S.¹, Budimir B.¹, Krpina K.¹, Bogdan M.¹

¹Special hospital for lung diseases, Pulmology, Zagreb, Croatia

EP22

Experience with alectinib as first-line treatment

Gábor Zsoldos¹, Zsolt Pápai-Székely¹

¹St. George's Hospital, Fejér County, Department of Pulmonology, Székesfehérvár, Hungary

EP23

Chronic Inflammation as Potential Predictive Factor of NivolumabTherapy in Non-small Cell Lung Cancer

Martin Svaton¹, Milada Zemanova², Jana Skrickova³, Lenka Jakubikova³, Vitezslav Kolek⁴ Juraj Kultán⁴, Leona Koubkova⁵, Alzbeta Bejckova⁵, Frantisek Salajka⁶, Michal Hrnčiarik⁶, Bohuslav Melichar⁷, David Vrana⁷, Marek Konecny⁸, Renata Chloupkova⁸, Milos Pesek¹

¹Department of Pneumology and Phtiseology, Charles University, Faculty of Medicine in Pilsen, Czech Republic; ²Department of Oncology, Charles University, First Faculty of Medicine in Prague, Czech Republic; ³Department of Respiratory Diseases and TB, Faculty of Medicine, Masaryk University Brno and University Hospital Brno, Czech Republic; ⁴Department of Pneumology and Phtiseology, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic; ⁵Department of Pneumology, Second Faculty of Medicine, Charles University Prague and Faculty Hospital Motol, Czech Republic; ⁶Department of Pneumology, Charles University, Faculty of Medicine in Hradec Kralove, Czech Republic; ⁷Department of Oncology, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic; ⁸Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

EP24

Side effects of immunotherapies in the practice of oncopulmonology

Attila Makai¹, Nóra Bittner¹

¹DEKK Pulmonology, Debrecen, Hungary

EP25

Long-term survival with atezolizumab-a case report

Zsófia Laura Török¹, István Ruzsics¹, Marianna Imre², Tibor Csere³, Gábor Smuk⁴, Veronika Sárosi¹

¹University of Pécs, I st. Dept. of Internal Medicine, Pulmonology, Pécs, Hungary; ²Pécsi Diagnosztikai Központ, Pécs, Hungary; ³University of Pécs, Dept. of Oncotherapy, Pécs, Hungary; ⁴University of Pécs, Dept. of Pathology, Pécs, Hungary

20:00

Networking dinner

23 November 2019
Saturday

09:00-10:45

Best of WCLC 1.

Chairs: Rudolf M. Huber, Peter Berzinec

Immunotherapy in NSCLC

Gyula Ostoros

National Koranyi Institute of Pulmonology, Budapest, Hungary

Management of small cell lung cancer

Nevena Secen

University of Novi Sad, School of Medicine, Novi Sad, Serbia

First-Line Atezolizumab plus Chemotherapy in Extensive Stage Small Cell Lung Cancer

Libor Havel

Thomayer Hospital, Prague, Czech Republic

Targeted therapies in NSCLC

Tanja Cufer

University Clinic Golnik, Golnik, Slovenia

Novel treatment of mesothelioma

Marko Jakopovic

University of Zagreb, School of Medicine, Department for Respiratory Diseases Jordanovac, University Hospital Center Zagreb, Zagreb, Croatia

Locally advanced disease

Robert Pirker

Department of Medicine I, Medical University of Vienna, Austria

Discussion

10:45-11:15

Coffee break

11:15-11:45

Pfizer Symposium - New therapeutic option in the sequential treatment of ALK positive NSCLC

Chair: Gabriella Gálffy

Open questions and answers in the sequential treatment of ALK+ NSCLC

Krisztina Bogos

National Koranyi Institute of Pulmonology, Budapest, Hungary

Third-generation ALK inhibitor in real world setting

Lilla Tamási

Semmelweis University, Budapest, Hungary

11:45-13:00

Best of WCLC 2.

Chairs: Nóra Bittner, Gunta Purkalne

Biomarkers in 2019

József Tímár

2nd Department of Pathology, Semmelweis University, Hungary

New Technics in Surgery

Mir Alireza Hoda

Medical University of Vienna, Vienna, Austria

Pulmonological comorbidities

Vitezslav Kolek

University Hospital Olomouc, Olomouc, Czech Republic

Novelties in Radiotherapy

Karmen Stanic

Institute of Oncology Ljubljana, Department of Radiotherapy, Slovenia

	Advances in Supportive Care <u>Krisztina Bogos</u> <i>National Koranyi Institute of Pulmonology, Budapest, Hungary</i>
13:00-13:30	Closing remarks